TNF Pharmaceuticals Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Chief executive officer
n/a
Total compensation
CEO salary percentage | n/a |
CEO tenure | no data |
CEO ownership | n/a |
Management average tenure | 1.5yrs |
Board average tenure | 3.7yrs |
Recent management updates
Recent updates
We Think MyMD Pharmaceuticals (NASDAQ:MYMD) Needs To Drive Business Growth Carefully
Sep 01We're Keeping An Eye On MyMD Pharmaceuticals' (NASDAQ:MYMD) Cash Burn Rate
May 19MyMD Pharma receives grant from European patent office for Supera-CBD compound
Aug 30Oramed, MyMD surge on plans for early-stage oral COVID vaccine data release in Q3
Jul 08Companies Like MyMD Pharmaceuticals (NASDAQ:MYMD) Could Be Quite Risky
Apr 12MyMD Pharmaceuticals (NASDAQ:MYMD) Is In A Good Position To Deliver On Growth Plans
Aug 29CEO
TNF Pharmaceuticals has no CEO, or we have no data on them.
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Interim Chief Financial Officer | 3.8yrs | US$162.00k | no data | |
President | less than a year | no data | no data | |
Investor Relations Officer | no data | no data | no data | |
Executive Vice President of Drug Development | 1.5yrs | no data | no data |
1.5yrs
Average Tenure
Experienced Management: TNFA's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
President | less than a year | no data | no data | |
Independent Chairman of the Board | 6.3yrs | US$216.00k | 0.11% $ 4.0k | |
Independent Director | less than a year | no data | no data | |
Director | 7.3yrs | US$310.89k | 0.11% $ 4.0k | |
Independent Director | 3.7yrs | US$96.00k | 0% $ 0 | |
Independent Director | 7.3yrs | US$96.00k | 0.089% $ 3.3k | |
Member of Scientific Advisory Board | no data | no data | no data | |
Independent Director | 3.7yrs | US$96.00k | 0% $ 0 |
3.7yrs
Average Tenure
58yo
Average Age
Experienced Board: TNFA's board of directors are considered experienced (3.7 years average tenure).
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/22 00:19 |
End of Day Share Price | 2024/12/20 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
TNF Pharmaceuticals, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|